Over the past ten years, a number of cytokines and growth factors have proven to be as effective therapeutics. While these products have certainly established recombinant biologics as a major pharmaceutical growth sector, the continued interest in this class of drugs arises from the fact that today we have a far better understanding of the human immune response, both at a cellular and molecular level. This has resulted in a more methodical characterisation of these factors which has given clinical researchers an opportunity to plan Phase 1 clinical trials that can provide substantial information on the activity of the cytokine in humans. Currently, a great deal of effort is also being channelled into identifying cytokines from the various DNA databases. Our major objective for this book is to profile cytokines that have been recently identified. The therapeutic potential of these cytokines based on their known properties will be discussed by the authors. The main aim of this book is to provide...|Over the past ten years, a number of cytokines and growth factors have proven to be as effective therapeutics. While these products have certainly established recombinant biologics as a major pharmaceutical growth sector, the continued interest in this class of drugs arises from the fact that today we have a far better understanding of the human immune response, both at a cellular and molecular level. This has resulted in a more methodical characterisation of these factors which has given clinical researchers an opportunity to plan Phase 1 clinical trials that can provide substantial information on the activity of the cytokine in humans. Currently, a great deal of effort is also being channelled into identifying cytokines from the various DNA databases. Our major objective for this book is to profile cytokines that have been recently identified. The therapeutic potential of these cytokines based on their known properties will be discussed by the authors. The main aim of this book is to provide...|Our major objective for this book is to profile cytokines that have been recently identified. The therapeutic potential of these cytokines based on their known properties will be discussed by the authors. The main aim of this book is to provide both academic and industry researchers with the current status of research with each of these cytokines and the development status of those that are already in clinical...
Interleukin 5.- Interleukin 10.- Interleukin 16.- Interleukin 17.- Interleukin 18.- FLJ3 ligand.- Keratinocyte growth factor-2.- Chemokines.
Over the past ten years, a number of cytokines and growth factors haveproven to be as effective therapeutics. While these products havecertainly established recombinant biologics as a major pharmaceuticalgrowth sector, the continued interest in this class of drugs arises fromthe fact that today we have a far better understanding of the humanimmune response, both at a cellular and molecular level.This has resulted in a more methodical characterisation of these factorswhich has given clinical researchers an opportunity to plan Phase 1clinical trials that can provide substantial information on the activityof the cytokine in humans. Currently, a great deal of effort is alsobeing channelled into identifying cytokines from the various DNAdatabases.Our major objective for this book is to profile cytokines that have beenrecently identified. The therapeutic potential of these cytokines basedon their known properties will be discussed by the authors. The main aimof this book is to provide...
Contents. List of Contributors. Cuss, F. M.: Interleukin 5. Narula, S., Smith, S. and Grint, P.: Interleukin 10. Cruikshank, W. W., Cornfeld, H. and Center, D. M.: Interleukin 16. Fossiez, F., Nicolas, J.-F. and Lebecque, S.: Interleukin 17. Kurimoto, M.: Interleukin 18. McKenna, H. J.: FLT3 Ligand. Jimenez, P. A., Greenwalt, D., Mendrick, D. L., Rampy, M. A., Su, J., Leung, K. H. and Connolly, K. M.: Keratinocyte Growth Factor. Lira, S. A., Zavodny, P. J. and Lundell, D.: Chemokines. Index
Our major objective for this book is to profile cytokines that have been
recently identified. The therapeutic potential of these cytokines based
on their known properties will be discussed by the authors. The main aim
of this book is to provide both academic and industry researchers with
the current status of research with each of these cytokines and the
development status of those that are already in clinical...
Inhaltsverzeichnis
Interleukin 5.- Interleukin 10.- Interleukin 16.- Interleukin 17.- Interleukin 18.- FLJ3 ligand.- Keratinocyte growth factor-2.- Chemokines.
Klappentext
Over the past ten years, a number of cytokines and growth factors have
proven to be as effective therapeutics. While these products have
certainly established recombinant biologics as a major pharmaceutical
growth sector, the continued interest in this class of drugs arises from
the fact that today we have a far better understanding of the human
immune response, both at a cellular and molecular level.
This has resulted in a more methodical characterisation of these factors
which has given clinical researchers an opportunity to plan Phase 1
clinical trials that can provide substantial information on the activity
of the cytokine in humans. Currently, a great deal of effort is also
being channelled into identifying cytokines from the various DNA
databases.
Our major objective for this book is to profile cytokines that have been
recently identified. The therapeutic potential of these cytokines based
on their known properties will be discussed by the authors. The main aim
of this book is to provide...
Our major objective for this book is to profile cytokines that have been
recently identified. The therapeutic potential of these cytokines based
on their known properties will be discussed by the authors. The main aim
of this book is to provide both academic and industry researchers with
the current status of research with each of these cytokines and the
development status of those that are already in clinical...